DS
MIRM icon

David Shaw’s Mirum Pharmaceuticals MIRM Stock Holding History

David Shaw’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.26M Sell
27,879
-139,610
-83% -$14M ﹤0.01% 2765
2026
Q1 		$15.5M Sell
167,489
-780,672
-82% -$73.4M 0.01% 1317
2025
Q4 		$74.9M Buy
948,161
+24,652
+3% +$1.77M 0.04% 521
2025
Q3 		$67.7M Buy
923,509
+368,552
+66% +$23.4M 0.04% 520
2025
Q2 		$28.2M Buy
554,957
+11,680
+2% +$520K 0.02% 838
2025
Q1 		$24.5M Buy
543,277
+385,925
+245% +$18.2M 0.02% 824
2024
Q4 		$6.51M Buy
+157,352
New +$6.56M ﹤0.01% 1777
2024
Q1 		– Sell
-22,178
Closed -$655K – 4584
2023
Q4 		$655K Sell
22,178
-1,146
-5% -$34.7K ﹤0.01% 3387
2023
Q3 		$737K Buy
+23,324
New +$639K ﹤0.01% 3243
2022
Q4 		– Sell
-36,145
Closed -$759K – 5001
2022
Q3 		$759K Buy
36,145
+11,309
+46% +$272K ﹤0.01% 3782
2022
Q2 		$483K Buy
+24,836
New +$586K ﹤0.01% 4108
2020
Q3 		– Sell
-10,581
Closed -$206K – 4026
2020
Q2 		$206K Buy
+10,581
New +$177K ﹤0.01% 3765

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's MIRM Position: Q2 2026 in Review

David Shaw reduced its Mirum Pharmaceuticals (MIRM) stake by 83% in Q2 2026, selling an estimated $14M and leaving 27,879 shares worth $3.26M. The position accounts for ﹤0.01% of the portfolio, ranked #2765.

David Shaw first reported a position in MIRM in Q2 2020 and has held it in 12 quarters since. The position peaked at $74.9M in Q4 2025. 326 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • David Shaw held 27,879 shares of Mirum Pharmaceuticals worth $3.26M as of Q2 2026.
  • David Shaw sold 139,610 Mirum Pharmaceuticals shares in Q2 2026, an estimated $14M.
  • Mirum Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2765 holding.
  • David Shaw first reported a position in Mirum Pharmaceuticals in Q2 2020 and has held it in 12 quarters since.
  • David Shaw's Mirum Pharmaceuticals position peaked at $74.9M in Q4 2025.
  • 326 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.